



Vol. 54, No. 2  
2020

# *The Bovine* **PRACTITIONER**

THE OFFICIAL PUBLICATION OF THE  
AMERICAN ASSOCIATION OF BOVINE PRACTITIONERS





# The Bovine PRACTITIONER

**EDITOR:**  
**ROBERT A. SMITH, DVM**  
3404 Live Oak Lane  
Stillwater, Oklahoma 74075  
Tel: (405) 743-9133  
Fax: (405) 743-8422  
cowdr@sbcglobal.net

**PUBLISHER:**  
**VM PUBLISHING COMPANY**  
205 W. 7th Avenue, Suite 201  
Stillwater, Oklahoma 74074  
Tel/Fax: (405) 533-1883  
kellijo.vmpubco@gmail.com

## OFFICERS

<b>President</b> .....	<b>Calvin Booker, DVM</b> Okotoks, AB, Canada
<b>President-Elect</b> .....	<b>Carie Telgen, DVM</b> Greenwich, New York
<b>Vice President</b> .....	<b>Pat Gorden, DVM</b> Ames, Iowa
<b>Past President</b> .....	<b>Glenn Rogers, DVM</b> Aledo, Texas
<b>Executive Director</b> .....	<b>K. Fred Gingrich II, DVM</b> Ashland, Ohio
<b>Treasurer</b> .....	<b>Brian Reed, DVM</b> Lititz, Pennsylvania
<b>Parliamentarian</b> .....	<b>Christine B. Navarre, DVM</b> Baton Rouge, Louisiana

## BOARD OF DIRECTORS

**Elizabeth H. Brock, DVM**  
St. Albans, Vermont  
1st District, 2023

**Randall H. Hinshaw, DVM**  
Rockingham, Virginia  
2nd District, 2021

**Lee Jones, DVM**  
Tifton, Georgia  
3rd District, 2022

**Mark E. Hardesty, DVM**  
Maria Stein, Ohio  
4th District, 2023

**Wilfred D. Schuler, DVM**  
Hazel Green, Wisconsin  
5th District, 2021

**Vickie L. Cooper, DVM**  
Ames, Iowa  
6th District, 2023

**Carl Meyer, Jr, DVM**  
Oskaloosa, Kansas  
7th District, 2023

**Arn A. Anderson, DVM**  
Bowie, Texas  
8th District, 2021

**Jeff D. Ondrak, DVM**  
Fairbury, Nebraska  
9th District, 2022

**Gerard J. Koenig, DVM**  
Tulare, California  
10th District, 2020

**Dale A. Moore, DVM**  
Moscow, Idaho  
11th District, 2021

**Murray Gillies, DVM**  
Sussex, New Brunswick, Canada  
12th District, 2022

**Eric Behlke, DVM**  
Okotoks, Alberta, Canada  
13th District, 2020

**AVMA DELEGATE:** **Brian J. Gerloff, DVM**  
Marengo, Illinois

**ADVERTISING AGENCY:** **J. T. O'Brien & Assoc.**  
12118 Nieman Road  
Overland Park, Kansas 66213  
(913) 579-4084

THE BOVINE PRACTITIONER is published by The American Association of Bovine Practitioners, at **VM Publishing Company, LLC, 205 W. 7th, Suite 201, Stillwater, OK 74074 (Telephone and Fax: (405) 533-1883)**. Copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to:

### AABP

**1130 East Main Street, Suite 302**  
**Ashland, Ohio 44805**  
**Tel: (419) 496-0685; FAX (419) 496-0697**  
**e-mail: aabphq@aabp.org**  
**http://www.aabp.org**

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in the spring and summer annually. It serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English. Beginning in 2019, THE BOVINE PRACTITIONER is an open access journal.

Copies of THE BOVINE PRACTITIONER are available to non-members. **Contact editor for details and subscription prices.**

# Table of Contents

Comparison of gamithromycin post-treatment intervals for beef cattle naturally affected with bovine respiratory disease  
*Miles E. Theurer, J. Trent Fox, Tom A. Portillo, Nathan F. Meyer, Douglas T. Ensley, David G. Renter* ..... 105

Comparison of three injectable metaphylactic antimicrobial treatments administered at feedlot arrival for control of bovine respiratory disease in calf-fed Holstein steers  
*Justin W. Buchanan, Ashley R. Nilles, Randall C. Raymond*..... 112

Influence of bovine viral diarrhea virus infections on AI conception and breeding season pregnancy success in vaccinated beef herds  
*Kaitlin M. Epperson, Jerica J. J. Rich, Saulo Menegatti Zoca, Stephanie D. Perkins, Emmalee J. Northrop, Russell F. Daly, Julie A. Walker, Jim R. Rhoades, George A. Perry*..... 120

Scrotal circumference at weaning in beef bulls and subsequent ability to pass a breeding soundness examination as a yearling  
*Tara H. Fountain, Robert L. Larson, Brad J. White* ..... 126

Progesterone release and incidence of bacteria following sterilization and reuse of controlled internal drug release devices (CIDRs)  
*B. Talsma, B.J. Fields, K.L. Vincent, W.B. Smith, J.L. Speshock, J. Waddell, D. Snyder, N.W. Dias, V.R.G. Mercadante, T. Jones, D.A. Roper*..... 130

Reducing bovine leukemia virus prevalence on a large midwestern dairy farm by using lymphocyte counts, ELISA antibody testing, and proviral load  
*Tasia M. Taxis, Tawnie N. DeJong, Cheryl L. Swenson, Kelly R.B. Sporer, Casey Droscha, Don Niles, Paul C. Bartlett* ..... 136



Cattle First.

## BVD VIRUS TYPE 1B IS ON THE RISE.

Bovine viral diarrhea (BVD) infection can disintegrate herd productivity. And if you're using a vaccine, like Bovi-Shield GOLD<sup>®</sup>, that isn't labeled for the most prevalent strain, your cattle could be at risk. Play it safe. Choose the only vaccines specifically labeled to protect against Type 1b: Express<sup>®</sup> FP and Pyramid<sup>®</sup> + Presponse<sup>®</sup> SQ. Know more at [BVDVTracker.com](http://BVDVTracker.com).

<sup>1</sup> Data on file, Boehringer Ingelheim and BVDVTracker.com. Data collected November 1, 2018 through November 1, 2020.  
<sup>2</sup> Ridpath JF, Lovell G, Neill JD, et al. Change in predominance of bovine viral diarrhea virus subgenotypes among samples submitted to a diagnostic laboratory over a 20-year time span. *J Vet Diagn Invest* 2011;23(2):185-193.

EXPRESS<sup>®</sup>, PYRAMID<sup>®</sup>, The PYRAMID Logo<sup>®</sup> and PRESPONSE<sup>®</sup> are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. The EXPRESS logo<sup>™</sup> is a trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are property of their respective owners. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0284-2019A-V2

**EXPRESS<sup>®</sup> FP**

**PYRAMID<sup>®</sup>  
+ PRESPONSE<sup>®</sup> SQ**



Metaphylaxis with tildipirosin did not inhibit effectiveness of an experimental monovalent vaccine of live, attenuated *Mannheimia haemolytica* administered intranasally to dairy calves  
*Scott Nordstrom, Michael Bolton, Kevin Hill, Tim Parks, Mani Vaidyanathan, Geert Vertenten, Kelly Lechtenberg*..... 145

Efficacy of a modified-live IBR-BVD-PI3-BRSV-*Mannheimia haemolytica* toxoid vaccine against challenge with virulent BHV-1 and PI3 viruses in calves 60 days of age  
*Aleksandar Masic, Suman Mahan, Brian Sobecki, Chadwick Brice, Sally Mattern, Dennis Peterson, Peter Barret, Colt Daugherty, Todd Meinert, Correas Ignacio, Moulin Véronique* ..... 153

The impact of future technological advancements on current bovine respiratory disease management practices  
*Jason S. Nickell, Lonty K. Bryant, Robert P. Lavan, Pedro Rodriguez Fernandez*..... 162

## Advertisers Index

Addison Biological Laboratory, Inc. .... inside front cover  
Boehringer Ingelheim Animal Health Inc. US ..... table of contents, back cover  
Merck Animal Health..... front of book

*Cover photo courtesy of Jennifer L. Nightingale, DVM, Countryside Veterinary Clinic, Lowville, NY.*

### Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.

**71%**

2020<sup>1</sup>

**61%**

2008<sup>2</sup>

**54%**

1998<sup>2</sup>

**41%**

1988<sup>2</sup>

Percent of all BVDV cases attributed to **TYPE 1B.**

**RELENTLESS PROTECTION**



## Editorial Review Board 2020

***The Bovine Practitioner* articles are reviewed by three Editorial Review Board members.  
Reviewers for 2020 included:**

Dr. David Anderson Knoxville, TN	Dr. Derek Foster Raleigh, NC	Dr. Kaitlyn Lutz Geneva, NY	Dr. Loren Schultz Columbia, MO
Dr. Kevin Anderson Raleigh, NC	Dr. Franklyn Garry Ft. Collins, CO	Dr. Matt Miesner Manhattan, KS	Dr. Jan Shearer Ames, IA
Dr. Chance Armstrong Baton Rouge, LA	Dr. Philippa Gibbons Speedwell, TN	Dr. Dale Moore Moscow, ID	Dr. Katie Simpson Fort Collins, CO
Dr. Ruth Blauwiekel Colchester, VT	Dr. John Gilliam Stillwater, OK	Dr. Pierre-Yves Mulon Knoxville, TN	Dr. David Smith Mississippi State, MS
Dr. Robert Callan Ft. Collins, CO	Dr. Sandra Godden St. Paul, MN	Dr. Christine Navarre Baton Rouge, IA	Dr. Lynn Steadman Chadron, NE
Dr. Vickie L. Cooper Ames, IA	Dr. Pat Gorden Ames, IA	Dr. Terri Ollivett Madison, WI	Dr. Gerald Stokka Cooperstown, ND
Dr. Robert Corbett Spring City, UT	Dr. Meggan Graves Knoxville, TN	Dr. Craig Payne Columbia, MO	Dr. Bill Stone Auburn, NY
Dr. Brent Credille Bishop, GA	Dr. Dee Griffin Canyon, TX	Dr. Dan Posey Amarillo, TX	Dr. Anthony Tarpoff Manhattan, KS
Dr. Russ Daly Brookings, SD	Dr. Brad Heins Watkinsville, GA	Dr. Jeremy G. Powell Fayetteville, AR	Dr. Miles Theurer Montezuma, KS
Dr. Lionel Dawson Stillwater, OK	Dr. Larry C. Hollis Flint, TX	Dr. D. Owen Rae Gainesville, FL	Dr. Dan Thomson Ames, IA
Dr. Andre Desrochers St-Hyacinthe, Quebec, Canada	Dr. Richard Hopper Auburn, AL	Dr. Ryan Rademacher Okotoks, Alberta, Canada	Dr. Michael Van Amburgh Ithaca, NY
Dr. Renee Dewell Ames, IA	Dr. Andy Johnson Green Bay, WI	Dr. Emily Reppert Manhattan, KS	Dr. Brian Vander Ley Clay Center, NE
Dr. Grant Dewell Ames, IA	Dr. Meredyth Jones Perkins, OK	Dr. John Richeson Canyon, TX	Dr. Kevin Washburn College Station, TX
Dr. Tyler Dohlman Ames, IA	Dr. Erin King Woodstock, CT	Dr. Karen Rogers Greeley, CO	Dr. Lou Anne Wolfe Claremore, OK
Dr. Terry Engelken Ames, IA	Dr. Jennifer Koziol West Lafayette, IN	Dr. Emmanuel Rollin Athens, GA	
Dr. Charles Estill Corvallis, OR	Dr. Brian Lubbers Manhattan, KS	Dr. Allen Roussel College Station, TX	

---

Appreciation is extended to each board member for volunteering their time and expertise to review articles for *The Bovine Practitioner*.

# READY. SET. ZUPREVO® (tildipirosin)

## When you spot bovine respiratory disease (BRD), reach for the fast that lasts.

Reaching **peak plasma levels in 45 minutes**, ZUPREVO gets to work rapidly. Its unique chemical structure results in swift accumulation in the lungs and keeps working **for 28 days** in lung tissue.<sup>1</sup>

With ZUPREVO, you can give clients the therapy they need to win the race against BRD. Fast-acting, long-lasting solutions are another way Merck Animal Health Works for you and your clients.

See the full prescribing information at [Zuprevo.com](http://Zuprevo.com).



<sup>1</sup>Menge M, et al. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, non-anesthetized cattle). *J Vet Pharmacol Ther.* 2012;35(6):550-559. The correlation between pharmacokinetic data and clinical relevance is unknown.

**IMPORTANT SAFETY INFORMATION: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN. RESIDUE WARNING:** Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residue. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. The effects of Zuprevo® 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter. **DO NOT USE ZUPREVO® 18% IN SWINE. FATAL ADVERSE EVENTS HAVE BEEN REPORTED FOLLOWING THE USE OF TILDIPIROSIN IN SWINE. NOT FOR USE IN CHICKENS OR TURKEYS.**

**PRODUCT INFORMATION**

NADA 141-334, Approved by FDA.

**ZUPREVO**<sup>®</sup> 18%  
(tildipirosin)

**Injectable Solution for Cattle****ANTIMICROBIAL DRUG**

180 mg of tildipirosin/mL. For subcutaneous injection in beef and non-lactating dairy cattle only.

**Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.**

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**BRIEF SUMMARY:** for full prescribing information use package insert.

**INDICATIONS:** Zuprevo<sup>®</sup> 18% is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni* in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, and *H. somni*.

**WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.**

Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.

For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.

For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800-211-3573. For additional Zuprevo 18% information go to [www.zuprevo.com](http://www.zuprevo.com).

For a complete listing of adverse reactions for Zuprevo 18% reported to CVM see: <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

**DO NOT USE ZUPREVO 18% IN SWINE.**

Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

**RESIDUE WARNING:** Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

**PRECAUTIONS:** The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

Made in Germany  
Distributed by: Intervet Inc d/b/a  
Merck Animal Health, Summit,  
NJ 07901 Copyright © 2011, Intervet Inc.,  
a subsidiary of Merck & Co. All rights reserved.

# Moraxella bovoculi Bacterin

## World's First Commercially Available Moraxella bovoculi Pinkeye Preventative!

- **8 Different M. bovoculi Isolates**
- **Cost Effective for All Cattle Herds**
- **Proven Safety Record**
- **More Convenient than Autogenous Programs**



Addison Biological Laboratory, Inc. announces the approval of the world's first commercial Moraxella bovoculi vaccine for the prevention of pinkeye in cattle. This USDA conditionally licensed product is the first of this kind. Previously the only method of prevention against *Moraxella bovoculi* was autogenous services. This vaccine signifies a breakthrough in convenience for the large number of veterinarians and herd owners battling the challenging problem of pinkeye caused by *Moraxella bovoculi*. This product license is conditional; efficacy and potency have not been fully demonstrated.



***From the LEADERS in pinkeye prevention!***



Addison Biological Laboratory, Inc.  
www.addisonlabs.com  
info@addisonlabs.com  
800-331-2530

